Andere Sprachen Aura Biosciences, Inc.

Aktien

A3C6D1

US05153U1079

AURA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 05.07.2024			% 5 Tage	% 1. Jan.
7.01 ^USD	+1.59%		-7.28%	-20.88%

29.05.	Transcript : Aura Biosciences, Inc. - Special Call
09.05.	Aura Biosciences, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Aura Biosciences : Corporate Presentation June 2024	04.06.
Aura Biosciences to Participate in the Jefferies Global Healthcare Conference	30.05.
Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024	23.05.
Aura Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights	09.05.
Aura Biosciences to Participate in Upcoming Investor Conferences	08.05.
Raj Parekh to Resign as Member of the Board of Directors of Aura Biosciences, Inc., Effective June 20, 2024	15.04.
Aura Biosciences Shares Rise Following Q4 Results	27.03.
Aura Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	27.03.
Aura Biosciences to Participate in Upcoming Investor Conferences	26.02.
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan for First-Line Treatment of Early-Stage Choroidal Melanoma	08.12.
Arix Bioscience's Portfolio Company Doses First Patient in Late-stage Trial of Choroidal Melanoma Therapy	08.12.
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma	07.12.
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-Sar) for First-Line Treatment of Early-Stage Choroidal Melanoma	07.12.
North American Morning Briefing : Stock Futures Hold Near Two-Month Highs	16.11.
Aura Biosciences Insider Bought Shares Worth $1,434,987, According to a Recent SEC Filing	09.11.
Aura Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09.11.
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights	09.11.
Aura Biosciences to Participate in Upcoming Investor Conferences	08.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Aura Biosciences, Inc.

Aktien

A3C6D1

US05153U1079

AURA

Andere Sprachen

Filter